前苏联专利SU1292668A3 Method of producing crystallized salts of cephem

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The invention relates to heterocyclic compounds, in particular, cephem (I) salts of the general formula S-CHo L C-C-® SUSH CH CH-CH-C-CHg | L tj g CH 2 lX 3-tv atomic C to room temperature. The process is conducted in an environment of water, ethanol or acetone. The desired product is isolated from the filtrate. Antibacterial activity is higher than that of known cephalosporins, since has a wider range of actions. Lflso L5H sulfate is 2000 mg / kg. 1 tab. I WITH
公开号:SU1292668A3
申请号:SU833680600
申请日:1983-12-26
公开日:1987-02-23
发明作者:Дюркхаймер Вальтер；Латтрелл Рудольф
申请人:Хехст Аг (Фирма)；
IPC主号:

专利说明:

112
This invention relates to the chemistry of heterocyclic compounds, and specifically to a process for the preparation of crystallized cephem salts of the general formula
t; J-GS-®A J A

CONH-r-r 1
Osne
. , FH 0 y4ji2 t
ftX
where X is NOj, I, C1, HOOCCH CHCOO, SO
item 1 or 2 5
which possess antibacterial activity.
The purpose of the invention is to develop an accessible method for producing compounds of the general formula (I),
Preparation of acid addition products to Compound II: 1-- | (BK, 7R) - (2-amino-4-thiazolyl) -glyoxy. p-amido -2-carboxy-8-oxo-5-thia-1 bicyclo 4.2. CjoKT-2, -en-3-yl methyl - -6,7-dihydro-5H-cyclopenta B 1 pyridine oxide, internal salt, 7 - (Z1- (0-methyloxime).
Example 1. Compound II dihydronitrate.
10.3 g (0.02 mol) of compound II are dissolved in 80 ml of water at room temperature and 100 ml of 0.85 n nitric acid are added at one time with shaking. The undissolved portion is immediately sucked off and washed with 10 ml of 0.85 N, nitric acid. Dihydronitrate crystallizes from the filtrate for 15 minutes. After 2 hours, stand at 5 ° C with suction, wash with 20 ml of 0.85 n. nitric acid and three times (50 ml each time) with diethyl ether. After drying at room temperature under vacuum, 9.8 g (7255% of theory) of colorless crystals are obtained; tf 138-140 ° C. By addition of the mother liquor in a vacuum, an additional 0.9 g (6.6%) of the product is obtained. 134 ° С “Mol” weight 676.65.
Calculated,%: C 39.05 H 4, G TS 16.56 S 9.48 HjO 5.32.
. 2N Oh, 2E ,, 0
Found,%: C 38.9 N 4.2 N, 16.6 S, 9.4 5.3.
H-NMR (CH, CO, jD): S 2.30-2.85 (m, 2Hj cyclopentene-H); 3 ,, 15--4.05 (m, 6H, 4-cyclopenten-H and SCH.) | 4.30 (S, 3N, OCH,), 5.20-6.35 (t, 4H, CHjPy and 2 Lactam-H); 7.65

20
) 26682
8.72 (t, 3N, P y); 9.22 ppm (S, 1H, tiaeol).
Example 2, Compound II dihydroiodide,
5 5.15 g (O, 01 mol) of compound II are dissolved in 80 ml of water and 25 ml of 1N is added. aqueous hydroiodic acid. After a short time, a colorless precipitate is formed. After hours at 20 ° C, the mixture is suction filtered and washed with 25 ml of cold water twice, each time with 20 ml. After drying in vacuum over 0, 6.4 g (83% of theory) of colorless crystals are obtained, i.e., 182-184 ° C. Mol weight 770.42.
Calculated,%: C 34.30 H 3.14 U 32.94 N 10.91 S 8.32
C.H.H.OjS ,. 2 on Found: C 33.3 H 3.7 J 33.5 N 10.5 S 8.3,
H-NMR (): 2.30-2.85 (m, 2H, cyclopenten-H); 3.10-4.05 (t, 6H, 4 cyclopenten-H and SCH2); 4.41 (S, ЗН, О ОСН); 5.25-6.20 (p, 4H, and 2-la-ctam-H) 8.11 (s, 1H, thiazole); 7.65-8.70 ppm (t, 3N, Ru).
Example 3, Sulfate of Compound I, J,
25.7 g (0.05 mol) of compound II are dissolved in 80 ml of water and with stirring 100 ml of 1N sulfuric acid are added with stirring and then 250 ml of ethanol. Minor tar-like contaminants are sucked off in this case through a filter with a brightening layer. Sulfate crystallizes out of the transparent filtrate for approximately 1 hour. After 3 hours, the mixture is suction filtered, washed with 40 ml of water and ethanol (1; 2), 1 ml of ethanol and twice with 30 ml. After drying for 3 days. 24.6 g (78% of theory) of colorless crystals are obtained over sulfuric acid at normal pressure; decomposition at 198–202 ° C, mol. weight 630.70.
Calculated,%: C 41.90 H 4.16 N 13.33 S 15.25 2.85.
C ,, H ,, N, 0, S ,. , - Found: C 41 ..90 H 4.2 N 13.4 S 15.0 HjO 2.3
thirty
45
- H-NMR (): b 2.00-2.60 (w, 2H, cyclopenten-H); 3.00-3.70 (ha, 6H, 4-cyclopenten-H and SCH); 4.03 (s, 3H, OCHj); 5.15-5.93 (m, 4H, CH., Py and 2-lactam-H); 7.1: (S, H, thiazole); 7, 66-8.62 pp (t, 3N, Ru).
3,
A. Dihydrochloride CO
Example II,
0.51 g (1 mmol) of compound II is dissolved in 4 ml of 0.5 and. hydrochloric acid. The solution is freeze-dried and the residue is evaporated with 8 ml of boiling ethanol. The insoluble resin is decanted and the solution is allowed to stand overnight at 3 ° C. The collected residue is sucked off, washed twice with ethanol (1 ml each time) and dried under vacuum over phosphorus pentoxide. Yield 250 mg (D1, from theory); decomposes from 190 C. Mol. mass 605, 54.
Calculated,%: C 43.64 H 4.33 C 1 1, 71 N 13.88 S 10.59 2.98
2HC1
Found: C42.6 H4.6 C 11, N 13.5 S 10.3 3.9.
H-NMR (CF,) G 2.20-2.85 (t 2H, cyclopenten-H) 3.10-4.02 (t, 6H, 4 cyclopenten-H and SCH2); 4.2 (S, 3N , OSI,); 5.26-6.28 (t, 4H, CKjPy and 2 lactam-H); 7.4 (s, 1H, thiazole); 7.68-8.75 ppm (in, 3H, Ru).
Example 5. Compound II dihydrobromide,
0.51 g (1 mmol) of compound II is dissolved in 4 ml of water and 5 ml of n is added. hydrobromic acid. After standing for a whole night, the precipitate is sucked off and washed three times with ice water, each time with 0.5 ml.

Compounds have the widest antibacterial spectrum with exceptional antibacterial activity.
After drying over phosphate-35 pentaoxide against clinically dependent: gram, 440 mg (63.5% of theory) of colorless crystals, t. . Mol mass 694.45.
Calculated,%: C 38.05 H 3.77 Bg 23.01 N 12.10 S 9.24 2.59 0
C, jH ,,,. 2НВг
Found: C 37.1 H 4.2 Vg 22.1 N 12.1 S 10.1 2.4.
H-NMR (CF,): S 2.20-2.80 (m, 2H, cyclopenten-H); 3.10-3.85 (t, 6H, 4 cyclopenten-H and CH2); 4.25 (S, 3N, OCH); 5.30-6.30 (t, 4H, and 2 lactam-H); 8.10 (3, 1H, thiazole; 7.65-8.90 ppm (t, 3N, Py).
Example 6: Compound II dihydromalealein 50,
45
positive (staphylococci, streptococci) and gram-negative embryos (sygnosis of a stick, Epterobacteriaceae). They are very active against many strains that are resistant against most older cephalosporins, for example streptococci of serogroup D (enterococci D), strains of blue-pus stumps and against bacteria forming jb-lactamase, for example E. coli TEM and Enterobacter cloacae P99.

权利要求:
Claims (1)
[1]
Invention Formula
3.1 g (6 mmol) of compound II and 1.74 g of maleic acid (15 mmol) were dissolved in 16 ml of water and 15 ml of acetone was added. A slight turbidity is sucked off and the clear filtrate is left overnight at. Educated residue
sucked off and washed with acetone / water (2: 1) twice in 10 ml portions. After drying in vacuum over phosphorus pentoxide for 2 hours at 60 ° C., 3.3 g (72% of theory) of colorless crystals are obtained, t. 137-39 ° C. A pier, mass 764.72.
O
five
0
Calculated,%: 0.99 S 8.39 C, H ,, N,
C 47.11 H 4.22
CaKgO,
H, 0
five
Found%: C 47.5 H 4.4 N 11.1 S 8.6.
n-NMR (): 2.25-13.85 (t, 2H, cyclopenten-H); 3.15-4.02 (t, 6H, 4 cyclopenten-H and SCH2); i 4.26 (S, -ZN, OSI); 5.25-6.10 (AB, 2H, CH.jPy); 5.42 (d, IH, I-5HZ, C-6-H); 6.32- (d, IH, C-7-H); 6.65 (S, 4H, maleic acid); 7.42 (S, IH, thiazole), 7.66-8.68 ppm (m, 3H, Py).
The LDg-p value for the compound of Example 3 is 2000 mg / kg mouse weight. The values for the remaining compounds will be in the same order.
The table shows the antibacterial activity of the proposed compounds compared with the antibacterial activity of known cephalosporins.
Compounds have the widest antibacterial spectrum with exceptional antibacterial activity.
ak against clinically dependent: gram
ak against clinically dependent: gram
positive (staphylococci, streptococci) and gram-negative embryos (sygnosis of a stick, Epterobacteriaceae). They are very active against many strains that are resistant against most older cephalosporins, for example streptococci of serogroup D (enterococci D), strains of blue-pus stumps and against bacteria forming jb-lactamase, for example E. coli TEM and Enterobacter cloacae P99.
Invention Formula
The method of obtaining crystallized cephem salts of the general formula
N-T-C-CONH-1-G
HaN SicH
C02H
X - NOj 5 If СЬ HOOCCH-CHCOOjSO ,.
n 1 or 2,
characterized in that cefembetine formula
N-r-C-CCfNH-r-r
7 P J U
icH Ш2Н
rt-pf f /
.
W.-wow
e-oram
(Antibacterial; MiCj mg / L actuality
Stapb, aureue SG 511
Strept,
pyogeiies 77A
Strejit. faeel.um D
Psead.aera- ginoiia ATCC
hell
Ebcolt TS
lpwina- aygüe
I
2 3
four
five
the famous
Cephalo rndii
Zefaudulin
Zefta-: eidn1ch
Cef-.- 1max
Cefti-, eoxim
Ceftrn-Aksov
Cefoperazon
0.31 0.31 0.31
0.3i 0.3
0.008 0.003, 0.008 0.008 0.003
12.5 12.5 3.13 6.25 6.25
0.015 0.0026.25:
1.25
iOCi
HOOO
, 95
6,250, i2 IOO0.78
f, 560,01510050
1.560: il, 2 i
1,560,0086,2562,5
0.780,127,66,25
Note. LD value for the compound according to Example 3 1: leaving 2000 mg / kg weight
Editor C, Baker
Compiled by Z.M. Kushev
Tehred A. Krae gu to the Correspondent A. Zimokos
Order 292/60 Circulation 372Subscription
VNIIPI State PC) 1 (1 Committee C (S.R.
for inventions and discoveries 113035, Moscow, Zh-35, Rzualska nab., d, 4/5
Production and printing company, Uzhgorod, Proektna St., 4
subjected to interaction with the acid of the formula
LF
where X and n are the indicated values, in the medium of an organic solvent at a temperature of from -5 ° C to komcat
Ebcolt TS
Klebs, aerog 15: r2E
Er.terobacter cloacal, P99
OO
five
eight
2 i
five
five
0.078 0.078 a, 078 0.078 0.078
125
500
0.5
0.078
0.039
0.039
500
0.078 0.062 0.062 0.078 0.062
62,: 5
0.5,
0.039
3.13
0.15
1.5.6
6.25 6.25 3.13 3.13 3., I3
1000
fOOO
00
250
250
250
500

类似技术:

公开号 | 公开日 | 专利标题

SU1292668A3|1987-02-23|Method of producing crystallized salts of cephem

FI74019C|1987-12-10|FOERFARANDE FOER FRAMSTAELLNING AV 7 -ACYLAMINO-3-SUBSTITUERADMETYL-3-CEFEM-4-CARBOXYLSYRADERIVAT.

US5026843A|1991-06-25|Process for the preparation of ceftriaxone

HU187068B|1985-11-28|Process for preparing crystallic benzenesulphonates of sulfamicilline

CS258143B2|1988-07-15|Method of crystalline solavate production

US4146710A|1979-03-27|Solid cephalosporin salt

EP1228074B1|2005-06-15|Method of preparing highly pure cefpodoxime proxetil

HU176287B|1981-01-28|Process for producing 7-bracket-2-thienylacetamido-bracket closed-3-triasolylthiomethyl-3-cepheme-4-carboxylic acid derivative

DE2558869C2|1982-09-23|Cephalosporins

Yasuda et al.1983|Synthesis and antibacterial activity of 6-and 7-[2-| phenylacetamido]-penicillins and cephalosporins

CA1216577A|1987-01-13|Crystalline 7-|-amino-3-| ceph-3-em-4-carboxylate

US3855211A|1974-12-17|Dithiocarbonylaminoacetyl cephalosporins

PL89245B1|1976-11-30|

US3971780A|1976-07-27|Thio-β-lactam cephalosporins

US3998950A|1976-12-21|7-αHydrazinoacetamido derivatives of cephalosporanic

EP0166580A2|1986-01-02|Improvements in or relating to ceftazidime

US4185015A|1980-01-22|Methoxymethyl 6-[D-2,2-dimethyl-4-|-5-oxo-1-imidazolyl]penicillanate

US3944546A|1976-03-16|Cyanomethylthioacetylcephalosporins

US3994889A|1976-11-30|3-Heterothio derivatives of |-7α-methoxy-cephalosporins

US3931170A|1976-01-06|3-Heterothio derivatives of |cephalosporins

US3971776A|1976-07-27|Thio-β-lactam penicillins

DE2222954C3|1976-02-19|Cephalosporins, processes for their manufacture and pharmaceutical agents

HU199849B|1990-03-28|New process for producing 6- square brackets open d-|-alpha-|-phenyl-acetamido square brackets closed penicillanic acid

US4025509A|1977-05-24|Aminopyridinium acetyl cephalosporanes

US3943130A|1976-03-09|[[|thiocarbonyl]oxy]acetyl cephalosporin derivatives

同族专利:

公开号 | 公开日

OA07622A|1985-03-31|

AU2289383A|1984-07-05|

DZ592A1|2004-09-13|

KR910000420B1|1991-01-25|

AR245133A1|1993-12-30|

PT77896A|1984-01-01|

FI76094B|1988-05-31|

FI834771A0|1983-12-23|

PH19269A|1986-02-21|

DK600183A|1984-06-29|

CS415791A3|1992-07-15|

KR840007016A|1984-12-04|

ES8407495A1|1984-09-16|

IL70544D0|1984-03-30|

ES528401A0|1984-09-16|

GR79444B|1984-10-30|

CA1235690A|1988-04-26|

CS997483A2|1985-07-16|

DE3381201D1|1990-03-15|

EP0112550A2|1984-07-04|

ZA839593B|1984-08-29|

IL70544A|1987-01-30|

FI76094C|1988-09-09|

AU562714B2|1987-06-18|

YU43200B|1989-04-30|

DK166211B|1993-03-22|

PT77896B|1986-04-21|

EP0112550B1|1990-02-07|

US4609653A|1986-09-02|

CS241070B2|1986-03-13|

IE56488B1|1991-08-14|

JPH0723382B2|1995-03-15|

IE833045L|1984-06-28|

NZ206704A|1986-04-11|

NO834824L|1984-06-29|

FI834771A|1984-06-29|

DD215552A5|1984-11-14|

MA19990A1|1984-07-01|

EP0112550A3|1985-09-18|

DK600183D0|1983-12-27|

AT50261T|1990-02-15|

HUT34211A|1985-02-28|

DK166211C|1993-08-16|

HU191385B|1987-02-27|

JPS59130888A|1984-07-27|

YU251183A|1986-06-30|

DE3248281A1|1984-06-28|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

JPH0250914B2|1979-05-25|1990-11-05|Glaxo Group Ltd|

FR2466469B1|1979-10-02|1984-02-10|Glaxo Group Ltd|

DE3279470D1|1981-04-03|1989-04-06|Fujisawa Pharmaceutical Co|New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds|

DE3118732A1|1981-05-12|1982-12-02|Hoechst Ag, 6000 Frankfurt|CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION|DE3118732A1|1981-05-12|1982-12-02|Hoechst Ag, 6000 Frankfurt|CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION|

JPH0516437B2|1983-12-29|1993-03-04|Mochida Pharm Co Ltd|

DE150507T1|1983-12-29|1987-02-26|Mochida Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp|CEPHALOSPORINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS.|

US4840945A|1985-04-01|1989-06-20|Mochida Pharmaceutical Co., Ltd.|Cephalosporin derivatives|

US5244891A|1985-08-05|1993-09-14|Bristol-Myers Squibb Company|Injectable compositions of cefepime dihydrochloride hydrate|

US4880798A|1986-11-25|1989-11-14|Mochida Pharmaceutical Co., Ltd.|Cephalosporin derivatives|

DE3706020A1|1987-02-25|1988-09-08|Hoechst Ag|CRYSTALLIZED CEPHEMIC ACID ADDITION SALTS AND METHOD FOR THE PRODUCTION THEREOF|

DE4440141A1|1994-11-10|1996-05-15|Hoechst Ag|Novel crystalline cephem acid addition salts and process for their preparation|

TW526202B|1998-11-27|2003-04-01|Shionogi & Amp Co|Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity|

DE60205882D1|2001-04-23|2005-10-06|Shionogi & Co|SULPHATE OF CEPHEM COMPOUND|

AU2003275682A1|2002-10-29|2004-05-25|Shionogi And Co., Ltd.|Crystal of inorganic acid salt of cephem compound|

CN101172982B|2006-11-03|2011-06-08|河北凯盛医药科技有限公司|Method of preparing cefpirome sulfate|

WO2008056221A2|2006-11-06|2008-05-15|Orchid Chemicals & Pharmaceuticals Limited|Crystalline sulfate salt of cephalosporin antibiotic|

CN101104621A|2007-05-08|2008-01-16|深圳信立泰药业股份有限公司|Technique for preparing high-purity cefpirome sulfate|

CN101284840B|2008-05-29|2012-07-04|管小明|Synthetic method of cefpirome sulfate|

CN103044455B|2011-10-17|2015-04-01|苏州中联化学制药有限公司|Reworking method of cefpirome sulfate mixed powder|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

DE19823248281|DE3248281A1|1982-12-28|1982-12-28|CRYSTALIZED CEPHEMIC ACID ADDITION SALTS AND METHOD FOR THE PRODUCTION THEREOF|LV930304A| LV5270A3|1982-12-28|1993-05-07|Satisfaction with crystallized cefema|

LTRP1113A| LT2528B|1982-12-28|1993-09-24|THE COST OF CEFEMO CRYSTALIZED SALT|

[返回顶部]